Trial Profile
A phase II/III, randomised, two-arm comparison of maintenance lapatinib versus placebo after first-line chemotherapy in patients with HER1 and/or HER2 overexpressing locally advanced or metastatic bladder cancer
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- Acronyms LaMB; OCTG-LaMB
- 17 Jun 2019 Status changed from active, no longer recruiting to completed.
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 01 Jan 2017 Results assessing efficacy of Lapatinib maintenance therapy published in the Journal of Clinical Oncology.